Guilin Sanjin Pharmaceutical Co Ltd (002275) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, manufacturing, and sale of traditional Chinese medicines in China and internationally.
Total Revenue Chart for Guilin Sanjin Pharmaceutical Co Ltd
Guilin Sanjin Pharmaceutical Co Ltd (002275) revenue for FY2025 was CNY 2.0B, a -6.8% change from FY2024. Guilin Sanjin Pharmaceutical Co Ltd's revenue grew from CNY 797.9M in 2006 to CNY 2.0B in 2025 (156.4% over 19 years). Earnings per share grew from CNY 0.52 in 2008 to CNY 0.56 in 2022 (8.8%). Revenue compound annual growth rate: 5-year CAGR of 5.5%, 10-year CAGR of 3.9%.
Total Revenue (CNY)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- ¥7.27B
- Implied Share Price
- ¥12.37
- Enterprise Value
- ¥6.20B
- Revenue (TTM)
- ¥2.02B
- EBITDA
- ¥646.32M
- Profit Margin
- 20.19%
- Trailing P/E
- 17.93
- Forward P/E
- 19.96
- Price/Book (MRQ)
- 2.23
- Price/Sales (TTM)
- 3.61
- EV/EBITDA
- 9.22
- EV/Revenue
- 3.07
- Dividend Yield
- 4.02%
- Book Value
- ¥5.51
- Free Cash Flow (FY2025)
- ¥621.18M
- Free Cash Flow Yield
- 8.55%
Snapshot as of 27th August 2026 — not point-in-time controlled, may lag the live market by a few days.